Loading...
•
Dec 31, 2022
Organon Q4 2022 Earnings Report
Organon's Q4 2022 performance saw a revenue decrease of 7% as-reported but increased by 1% ex-FX, with growth in Women's Health and Biosimilars partially offset by declines in Established Brands.
Key Takeaways
Organon reported a decrease in revenue of 7% as-reported but an increase of 1% ex-FX for Q4 2022. Women's Health and Biosimilars revenue increased, while Established Brands revenue declined. Net income was $108 million, or $0.42 per diluted share, and non-GAAP adjusted net income was $208 million, or $0.81 per diluted share.
Total revenue was $1,485 million, a decrease of 7% as-reported and an increase of 1% excluding the impact of foreign currency (ex-FX).
Women’s Health revenue increased 4% as-reported, and 9% ex-FX driven primarily by Nexplanon.
Biosimilars revenue increased 13% as-reported and 17% ex-FX.
Established Brands revenue decreased 14% as-reported and 4% ex-FX.
Forward Guidance
Organon does not provide GAAP financial measures on a forward-looking basis because the company cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts, and acquisition-related expenses.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...